miRoncol, a medtech startup, announced the successful completion of proof-of-concept studies for its multi-cancer early detection blood test. The test uses microRNA analysis and machine learning to detect cancers in their earliest stages, well before symptoms emerge. This technology leverages recent discoveries recognized by the 2024 Nobel Prize in Physiology or Medicine, which highlighted the critical role of microRNAs in disease regulation.
In studies involving over 11,000 blood samples, miRoncol’s test demonstrated impressive results. It accurately detects 12 types of cancer, representing around 60% of all cancer deaths, with a sensitivity of over 90%, meaning it correctly identifies cancer cases. The test also boasts 99% specificity, minimizing false positives. The ability to detect early-stage cancers with high accuracy could significantly enhance early intervention opportunities, improving patient survival rates.
miRoncol plans to proceed with validation studies before launching the test from Canada. This new technology holds potential not only to detect cancers earlier and more accurately, but also to reduce healthcare costs by minimizing the need for invasive diagnostic procedures. If successful, the test could revolutionize cancer diagnostics and patient care.
Click here to read the original news story.